Saturday, May 4, 2024
Home Biotech News Diabetes Page 3

Diabetes

    Most popular
    Provention

    Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)

    Diabetes Editor / Curator -
    Teplizumab: Can We Delay the Onset of Type 1? Last updated: 6/7/21 By Dr. Francine...
    Provention

    Provention Bio (PRVB) Updates.

    2021 Watch List Editor / Curator -
    LATEST UPDATE July 13th, 2022, below. (2021) We're getting way too many calls on...

    Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.

    Diabetes Editor / Curator -
    The 2021 Biotech Six Pack: Stocks We Expect to Double! These are ideas #3 and #4 for the 'Biotech...
    Citius

    Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.

    Biotech News Editor / Curator -
    Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today. We're beginning to believe (and...

    Adding ENDRA Life Sciences (NDRA) $0.89 to Watch List.

    Biotech News Editor / Curator -
    Another Fatty Liver Idea. This Time a Play on Detecting Fatty Liver Non-Invasively. Heads Up. Nearing Resistance at $0.89.
    Cyclophilin, Biotech Stock Review

    Adding Hepion Pharma (HEPA) $1.73 to Watch List.

    Biotech News Editor / Curator -
    Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here? Oh my…and Oh boy....
    123Page 3 of 3

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.